ClinicalTrials.gg
WithdrawnNCT02298816HMvax-RegistUpdated Oct 3, 2024

B-Cell Hematologic Malignancy Vaccination Registry

An observational study in Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma and Waldenstrom Macroglobulinemia, sponsored by Wake Forest University Health Sciences. Withdrawn at 1 site in United States. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Wake Forest University Health Sciences · Observational

Why this study was withdrawn
No patients enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Monoclonal Gammopathy of Undetermined Significance · United States.

Enrollment
20th of 20
0 · median 217
Started
2014
with 2 others
Observational
20 of 76
10 open now
Registered
53rd of 76
by date
Lead sponsor
3 of 76
Wake Forest University Health Sciences

Among the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, this one is the 20th largest by enrollment of the 20 observational ones that give a count, is one of 3 that started in 2014, is one of 20 observational ones, and was the 53rd registered.

Monoclonal Gammopathy of Undetermined Significance

102 studies on the registry are indexed under Monoclonal Gammopathy of Undetermined Significance; 28 are open to participants now.

Browse Monoclonal Gammopathy of Undetermined Significance studies →

Open to participants now

15 of the 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Monoclonal Gammopathy of Undetermined Significance studies recruiting now, 18 (90%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Monoclonal Gammopathy of Undetermined Significance with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to develop a vaccination registry system for Aurora Health Care patients newly diagnosed with MM and other B-Cell Hematologic Malignancies in order to prospectively characterize vaccination history and outcomes such as infection in these patients at Aurora Health Care. Additionally hospitalization rates, cost analysis, infection (influenza, pneumonia, other) related to vaccination in this patient population will be evaluated.

Read the detailed description

This is a prospective registry study on the immunizations in patients with B-Cell Hematologic Malignancies at Aurora Health Care. This observational study will consist of prospective medical record review of Aurora Health Care patients newly diagnosed B-Cell Hematologic Malignancies and will be used to characterize vaccination history, infection rate, and hospitalization rate. This is the second study in the series of studies designed to provide important information about the best way and time to vaccinate patients with MM and similar cancers to flu and pneumonia and to gather additional information about immune function in this patient population.

The registry will include all adult patients who are newly diagnosed with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL). The prevalence of newly diagnosed B-Cell Hematologic Malignancies at Aurora Health Care is approximately 1000 patients annually. This registry will be ongoing to collect real time data, with no definite sample size planned; however, data will be collected for at least 10 years. This time frame is based on Surveillance, Epidemiology, and End Results Program (SEER) data. There is a 50% survival rate at 5 years after diagnosis for MM, so the 10 year time frame will be able to capture long term outcome in patients.

Medical record information will be obtained through electronic data capture by Aurora Health Care staff with access to the electronic medical records. Data will be manually reviewed by the coordinator, Investigator and co-investigators for accuracy and completeness, to the extent available in the clinical medical record. Additionally, a biostatistician will assist in data analysis.

Descriptive statistics such as counts, proportions or percentages for category variables and mean and standard deviation for continuous variables will be computed for the all the variables. Depending upon the distribution of the category variables appropriate statistical tests such as chi-square and/or Fisher exact test will be used to find out the statistical significance. For continuous variables an appropriate statistical test such as t-tests and/or F test will be used.

This registry will be used for this research study, and may be queried for internal quality improvement projects as well. The principal investigator will be responsible for the overall monitoring of the data and safety of study participants/data integrity, with the assistance of other study team members.

03

Conditions studied

  • Monoclonal Gammopathy of Undetermined Significance
  • Multiple Myeloma
  • Waldenstrom Macroglobulinemia
  • Lymphocytosis
  • Lymphoma, Non-Hodgkin
  • B-Cell Chronic Lymphocytic Leukemia
  • Hematological Malignancies

Keywords

  • Monoclonal gammopathy of undetermined significance (MGUS)
  • Smoldering multiple myeloma (SMM)
  • Multiple myeloma (MM)
  • Waldenstroms Macroglobulinemia (WM)
  • Monoclonal B-cell lymphocytosis (MBL)
  • Chronic lymphocytic leukemia (CLL)
  • B-Cell Non-Hodgkin lymphoma (NHL)
  • B-Cell Hematologic Malignancies
  • immunization
  • Vaccination
  • Influenza, Human
  • Pneumonia
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients at Aurora Health Care who are newly diagnosed with:

  • Monoclonal gammopathy of undetermined significance (MGUS),
  • Smoldering multiple myeloma (SMM),
  • Multiple myeloma (MM),
  • Waldenstroms Macroglobulinemia (WM),
  • Monoclonal B-cell lymphocytosis (MBL),
  • Chronic lymphocytic leukemia (CLL), or
  • B-Cell Non-Hodgkin lymphoma (NHL).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients at Aurora Health Care who are newly diagnosed with:

    • Monoclonal gammopathy of undetermined significance (MGUS),
    • Smoldering multiple myeloma (SMM),
    • Multiple myeloma (MM),
    • Waldenstroms Macroglobulinemia (WM),
    • Monoclonal B-cell lymphocytosis (MBL),
    • Chronic lymphocytic leukemia (CLL), or
    • B-Cell Non-Hodgkin lymphoma (NHL).

Exclusion criteria

Exclusion Criteria:

  • none
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
10 Years
Patient registry
Yes

Groups and cohorts

  • new B-Cell Hematologic Malignancy diagnosis

    All adult patients who are newly diagnosed at Aurora Health Care with the following B-Cell Hematologic Malignancies: Monoclonal gammopathy of undetermined significance (MGUS), Smoldering multiple myeloma (SMM), Multiple myeloma (MM), Waldenstroms Macroglobulinemia (WM), Monoclonal B-cell lymphocytosis (MBL), Chronic lymphocytic leukemia (CLL), or B-Cell Non-Hodgkin lymphoma (NHL).

06

What researchers measure

Primary outcomes

  1. vaccination history

    Information regarding vaccination history will be collected historically and throughout data collection, expected to continue for about 10 years.

    Time frame: 10 years

Secondary outcomes

  1. Survival

    Survival status will be collected throughout data collection, expected to continue for about 10 years.

    Time frame: 10 years

  2. infection

    Information about any infections (influenza, pneumonia, other) such as numbers, types will be collected throughout data collection, expected to continue for about 10 years.

    Time frame: 10 years

  3. hospitalization rates

    Information regarding hospitalization will be collected throughout data collection, expected to continue for about 10 years.

    Time frame: 10 years

07

Study locations

1 site
  • Aurora Health Care
    Milwaukee, Wisconsin 53233, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2014 (actual). Primary completion is estimated for Dec 2024, 124 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 24, 2014
StartActual
Aug 2014
Primary completionEst.
Dec 2024
CompletionEst.
Dec 2025
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02298816
Collaborators
Vince Lombardi Cancer Clinic
Responsible party
Sponsor
First posted
Nov 24, 2014
Start date
Aug 2014
Primary completion
Dec 2024 (estimated)
Completion
Dec 2025 (estimated)
Last update
Oct 3, 2024

Study contacts

Michael Thompson, MD, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion